About
Contact & Profiles
A5085861688
Research Areas
- European and International Law Studies
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Innovations in Education and Learning Technologies
- Theology and Canon Law Studies
- Educational Methods and Teacher Development
- Legal Rights and Human Rights
- Advanced Breast Cancer Therapies
- European Criminal Justice and Data Protection
- Language, Communication, and Linguistic Studies
Moscow City Oncology Hospital №62
2023
Ural State Law University
2020-2022
e15561 Background: Regorafenib is considered the standard third-line therapy of mCRC. However, modest efficacy and significant toxicity regorafenib urges search for new therapeutic approaches. In various countries, re-challenge previously effective treatment regimens being considered. We compared effectiveness variants systemic in third subsequent lines treatment. Methods: analyzed prospective database pts with mCRC from two clinics Russian Federation. The statistical hypothesis implied...
10.1200/jco.2023.41.16_suppl.e15561
article
EN
Journal of Clinical Oncology
2023-06-01
10.34076/2219-6838-2020-5-82-88
article
EN
cc-by-nc-nd
Electronic supplement to Russian Juridical Journal
2020-01-01
10.34076/22196838_2022_3_57
article
EN
cc-by-nc-nd
Electronic supplement to Russian Juridical Journal
2022-01-01
10.34076/22196838_2021_1_77
article
EN
cc-by-nc-nd
Electronic supplement to Russian Juridical Journal
2021-01-01
10.34076/20713797_2021_3_179
article
EN
Russian Juridical Journal
2021-01-01
Coming Soon ...